Alkermes PLC is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for central nervous system (CNS) disorders. The company was founded in 1987 and is headquartered in Dublin, Ireland. Since its inception, Alkermes has been committed to improving the lives of patients with CNS disorders through the development of novel treatments.
One of Alkermes' flagship products is VIVITROL, a medication used to treat opioid dependence. VIVITROL is an extended-release formulation of naltrexone that is administered as a monthly injection. The medication has been shown to be effective in reducing opioid cravings and preventing relapse in patients with opioid dependence. VIVITROL has been approved for use in the United States and is also available in other countries around the world.
In addition to its work on opioid dependence, Alkermes is also developing therapies for other CNS disorders, including schizophrenia, bipolar disorder, and major depressive disorder. The company's pipeline includes several promising drug candidates, including ALKS 3831, a combination therapy for the treatment of schizophrenia and bipolar disorder.
Alkermes is also committed to innovation in drug delivery technology. The company has developed several proprietary technologies that enable the targeted delivery of medications to the CNS, including its proprietary NanoCrystal technology and its ProLease technology. These technologies are designed to improve the efficacy and tolerability of CNS therapies and enhance patient outcomes.
Alkermes PLC is a biopharmaceutical company that is making significant strides in the development of innovative therapies for CNS disorders. With its focus on opioid dependence, schizophrenia, bipolar disorder, and major depressive disorder, Alkermes has the potential to make a significant impact on the lives of millions of people worldwide who are affected by these conditions. As the company continues to advance its drug development programs and invest in innovative drug delivery technologies, it will undoubtedly attract the attention of investors and stakeholders looking to support the development of new therapies for unmet medical needs in the CNS space.
YES YOU CAN GO BLOCKCHAIN DIRECTORY - RESERVE YOUR BLOCKCHAIN DOMAIN HERE